Upstream Bio (UPB) Preferred Stock Liabilities (2023 - 2024)
Upstream Bio (UPB) posted quarterly Preferred Stock Liabilities of $380.9 million for Q3 2024, up 64.93% year-over-year from $230.9 million in Q4 2023, and little changed quarter-over-quarter from $380.9 million in Q2 2024.
Powered by 
Analysis
Upstream Bio (UPB) Preferred Stock Liabilities (2023 - 2024) Analysis & Trends
Upstream Bio's Preferred Stock Liabilities history runs 2 years deep, the most recent figure standing at $380.9 million for Q3 2024.
- In Q3 2024, Preferred Stock Liabilities rose 64.93% year-over-year to $380.9 million; the TTM figure through Sep 2024 stood at $380.9 million (up 64.93% YoY), while the FY2023 annual figure was $230.9 million, changed N/A from the prior year.
- Preferred Stock Liabilities for Q3 2024 stood at $380.9 million, roughly flat from $380.9 million in the prior quarter.
- The five-year high for Preferred Stock Liabilities was $380.9 million in Q2 2024, with the low at $230.9 million in Q3 2023.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Upstream Bio | 327.95 Mn | 327.95 Mn | -3.29 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2024 | 380.87 Mn |
| Jun 30, 2024 | 380.87 Mn |
| Mar 31, 2024 | 230.94 Mn |
| Dec 31, 2023 | 230.94 Mn |
| Sep 30, 2023 | 230.94 Mn |